GlassScriptPhysician profile
Suketu Shah
NPI 1124050570
$5,396.95
in general payments reported to CMS, 2019-2025
51 companies · $847 in 2025
The $847 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,022 · 2020: $497 · 2021: $547 · 2022: $99.51 · 2023: $647 · 2024: $737 · 2025: $847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,230.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,969.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $404.34 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Mannkind Corporation | $204.97 | 2019-2025 | |
| Corcept Therapeutics | $203.95 | 2019-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $189.91 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $188.70 | 2019-2023 | Delstrigo, Dificid, Pifeltro |
| Radius Health, INC. | $170.52 | 2019-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.12 | 2019-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $147.18 | 2023-2025 | Gvoke Hypopen |
| Insulet Corporation | $138.40 | 2023-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $120.55 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $113.01 | 2019-2022 | |
| Alvogen INC | $96.48 | 2023-2025 | Teriparatide |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.33 | 2019-2024 | Cycloset |
| Abbott Laboratories | $80.96 | 2019-2022 |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $74.61 | 2024-2025 | Minimed 780g |
| Abbvie INC. | $71.65 | 2019-2023 | Synthroid |
| Antares Pharma, INC. | $61.79 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $57.21 | 2019 | |
| Janssen Pharmaceuticals, INC | $57.00 | 2019 | |
| Recordati_rare_diseases_inc. | $50.77 | 2023-2025 | Isturisa, Signifor Lar |
| Amgen INC. | $49.64 | 2023-2025 | Evenity, Prolia |
| Cequr Corporation | $49.20 | 2023-2024 | Cequr Simplicity |
| Lifescan, INC. | $48.47 | 2019-2021 | |
| Nalpropion Pharmaceuticals LLC | $45.45 | 2019 | |
| Eisai INC. | $39.97 | 2019 | |
| Amarin Pharma, INC. | $38.96 | 2019-2020 | |
| Ibsa Pharma INC. | $34.24 | 2019-2020 | |
| Endo USA, INC. | $31.94 | 2025 | Aveed |
| Vivus LLC | $29.21 | 2019-2020 | |
| Sanofi Pasteur INC. | $26.24 | 2019-2020 | |
| Dexcom, INC. | $26.07 | 2019-2022 | |
| Beta Bionics, INC. | $25.05 | 2023 | Ilet Bionic Pancreas |
| Rgh Enterprises LLC | $21.86 | 2025 | |
| Ascensia Diabetes Care US INC. | $21.04 | 2025 | |
| Becton, Dickinson and Company | $19.65 | 2019 | |
| Valeritas, INC. | $19.48 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $19.14 | 2023 | Somatuline Depot |
| Madrigal Pharmaceuticals | $18.97 | 2025 | Rezdiffra |
| Acella Pharmaceuticals, LLC | $17.56 | 2025 | NP Thyroid 60 |
| Novartis Pharmaceuticals Corporation | $15.75 | 2023 | |
| Amphastar Pharmaceuticals, INC. | $15.31 | 2023 | Baqsimi |
| Theratechnologies INC. | $15.00 | 2019 | |
| Gilead Sciences, INC. | $14.99 | 2024 | |
| Shire North American Group INC | $14.92 | 2019 | |
| Embecta Corp. | $14.90 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Sequel Med Tech, LLC | $14.85 | 2025 | Twiist |
| Pfizer INC. | $14.73 | 2019 | |
| Aytu Biopharma, INC. | $14.02 | 2019 | |
| Currax Pharmaceuticals LLC | $13.99 | 2019 | |
| Janssen Biotech, INC. | $13.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suketu Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.